Regorafenib with or without a programmed cell death protein 1 antibody as third‐line treatment for microsatellite stable metastatic colorectal cancer

BACKGROUND: Although the use of regorafenib plus nivolumab demonstrates promising outcomes in patients with refractory microsatellite stable (MSS) metastatic colorectal cancer (mCRC), this effect has not been substantiated in other studies. Moreover, a comparison between the outcomes of regorafenib...

Descripción completa

Detalles Bibliográficos
Autores principales: He, Wen‐Zhuo, Wang, Lei, Yin, Chen‐Xi, Yi, Jia‐Hong, Jin, Ya‐Nan, Jiang, Chang, Guo, Gui‐Fang, Xia, Liang‐Ping
Formato: Online Artículo Texto
Lenguaje:English
Publicado: John Wiley and Sons Inc. 2022
Materias:
RESEARCH ARTICLES
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10067040/
https://www.ncbi.nlm.nih.gov/pubmed/36373163
http://dx.doi.org/10.1002/cam4.5417

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10067040/
https://www.ncbi.nlm.nih.gov/pubmed/36373163
http://dx.doi.org/10.1002/cam4.5417

Ejemplares similares